Clozapine and the Gastrointestinal Tract-View Presentation

Video Transcription

Video Summary

In a recent SMI Advisor webinar, hosted by Professor Megan Arrett, Dr. Susanna Everey-Palmer from the University of Otago presented on "Clozapine and the Gastrointestinal Tract." The webinar, eligible for AMA and Nursing credits, discussed clozapine's impact on gastrointestinal (GI) motility, focusing on the condition known as clozapine-induced gastrointestinal hypomotility (CIGH), or slow gut. This side effect, manifesting in reduced gut motility, can lead to life-threatening bowel obstructions. Dr. Everey-Palmer highlighted that slow gut is often a significant but silent side effect, with severity not always predicted by self-reported constipation. <br /><br />Dr. Everey-Palmer, an expert in psychiatric treatment, stressed the importance of proactive management in clozapine patients, recommending prophylactic laxative use at the onset of treatment to mitigate risks. The presentation included clinical insights, the historical context of clozapine use, and management recommendations using the Porirua protocol which involves SENA and Macrogol. The session concluded with a Q&A, emphasizing the need for continual monitoring of patients and addressing GI symptoms promptly in clozapine-treated individuals to avert severe complications.

Keywords

Clozapine

Gastrointestinal Tract

Clozapine-Induced Gastrointestinal Hypomotility

GI Motility

Bowel Obstructions

Prophylactic Laxatives

Porirua Protocol

SENA and Macrogol

Psychiatric Treatment